Trump summons top officials after drug prices rise

President Trump summoned top officials for a meeting at the White House on Jan. 8, Politico reported. The meeting comes as major drugmakers raised prices at the start of the year, prompting a Twitter response from the president.

Officials attending the meeting included HHS Secretary Alex Azar, Council of Economic Advisers Chairman Kevin Hassett and acting White House Chief of Staff Mick Mulvaney, according to Politico.

The meeting also comes as a new report revealed the rising costs of prescription drugs are due to price increases by manufacturers rather than new, expensive therapies or improvements to medications already in existence.

Lowering prescription drug prices has been a focus for the Trump administration, but so far, policy proposals have taken aim at Medicare Part B and forced drugmakers to publish some prices online.

Beyond proposals, the president also lashed out at pharmaceutical companies directly via Twitter in 2018. Those actions prompted temporary halts to planned drug price hikes at Pfizer and Novartis. However, these steps were only temporary, as Pfizer announced it would raise prices of at least 41 drugs in 2019.

Drug prices rose on more than 250 medicines by 6.3 percent on average on Jan. 1, Politico reported, citing information from Rx Savings Solutions.

“Drug makers and companies are not living up to their commitments on pricing. Not being fair to the consumer, or to our Country!” Trump tweeted on Jan. 5.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup